首页> 美国卫生研究院文献>Gut Microbes >Guide to designing conducting publishing and communicating results of clinical studies involving probiotic applications in human participants
【2h】

Guide to designing conducting publishing and communicating results of clinical studies involving probiotic applications in human participants

机译:设计进行发表和交流涉及益生菌在人类受试者中应用的临床研究结果的指南

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

The heterogeneity of human clinical trials to assess the effectiveness of probiotics presents challenges regarding interpretation and comparison. Evidence obtained from clinical trials among a population with a disease or specific risk factors may not be generalizable to healthy individuals. The evaluation of interventions in healthy persons requires careful selection of outcomes due to the absence of health indicators and the low incidence of preventable conditions. Given the tremendous resources invested in such trials, development of consistent approaches to assessing the effectiveness of probiotics would be beneficial. Furthermore, the reporting, presentation and communication of results may also affect the validity of the scientific evidence obtained from a trial. This review outlines the challenges associated with the design, implementation, data analysis and interpretation of clinical trials in humans involving probiotics. Best practices related to their design are offered along with recommendations for enhanced collaboration to advance research in this emerging field.
机译:人类临床试验评估益生菌有效性的异质性对解释和比较提出了挑战。从患有疾病或特定危险因素的人群中通过临床试验获得的证据可能无法推广到健康个体。由于缺乏健康指标并且可预防疾病的发生率较低,因此对健康人的干预措施的评估需要仔细选择结果。鉴于在此类试验中投入了大量资源,开发一致的方法来评估益生菌的有效性将是有益的。此外,结果的报告,陈述和交流也可能影响从试验获得的科学证据的有效性。这篇综述概述了与涉及益生菌的人类临床试验的设计,实施,数据分析和解释相关的挑战。提供了与它们的设计相关的最佳实践,并提供了一些建议,以加强协作以推进这一新兴领域的研究。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号